Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00760474 · ClinicalTrials.gov registry record · Phase 1
An fMRI Study Of Brain Response In Patients With Fibromyalgia
A Phase 1 study, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT00760474 is a Phase 1 study that has completed, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 27 participants.
The verdict
NCT00760474, a Phase 1 study, has completed, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
The purpose of this study is to explore how pregabalin works in patients with fibromyalgia by evaluating brain imaging signals. To find out whether fMRI (functional magnetic resonance imaging) is an efficient way to show whether new pain medications are effective in treating fibromyalgia.
Interventions
- DRUG Pregabalin, then placebo
- DRUG Placebo, then pregabalin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2009-01 |
| Est. Completion | 2011-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00760474
The ClinicalTrials.gov registry entry for NCT00760474 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pregabalin, then placebo is the first listed.
NCT00760474 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00760474 about?
NCT00760474 is a clinical study titled "An fMRI Study Of Brain Response In Patients With Fibromyalgia". The purpose of this study is to explore how pregabalin works in patients with fibromyalgia by evaluating brain imaging signals. To find out whether fMRI (functional magnetic resonance imaging) is an efficient way to show whether new pain medications are effective in treating fibromyalgia.
What is the current status of trial NCT00760474?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2009-01. Estimated completion is 2011-03.
What interventions are being tested in trial NCT00760474?
The interventions under investigation include: Pregabalin, then placebo (DRUG), Placebo, then pregabalin (DRUG).
Who is sponsoring clinical trial NCT00760474?
This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.